Novartis AG (SWX:NOVN)
128.28
-3.20 (-2.43%)
Nov 19, 2026, 10:45 AM CET
← View all transcripts
Meet Novartis Management 2026 Part 1
Nov 19, 2026
Summary
Sales growth guidance is 5% for 2026-2031, with mid-single-digit average growth targeted through 2035 and a 40% core margin by 2029. Management highlighted an expanding late-stage pipeline, AI-driven productivity and U.S. manufacturing expansion.
All right. All right. Hello, everyone, and welcome to Meet Novartis Management 2026. Thank you, as always, for being here and for your interest in Novartis. We will start today with a presentation by Vas, followed by a Q&A with our corporate speakers, including Mukul, Ronnie, and Steffen. From there, we will go into our breakout groups on our therapeutic areas before coming back together here at the end of the day for a panel discussion on AI and R&D. One quick request for the webcast Q&A sessions. If you could please state your name and firm when asking a question, and also limit yourself to one question, please, if you can. Before we begin, I will just read the safe harbor statement. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors.
These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the U.S. Securities and Exchange Commission. With that, I will hand it over to Vas.
Perfect. All right. Thank you, Sloan, and thanks, everybody, for being here today. We are always grateful for all of you coming to Meet Novartis Management. We think it is a special event. You get to interact with our incredible people. I truly believe we have the best people in the industry, and you all can now have a conversation with them about why we are so excited about the future. Our hope is that you just take away three things from the event. One is our confidence in the next five years, where we have guided to the 5% growth that I will talk a little bit more about in a moment. Our confidence in our midterm guidance as well, and I want to try to help bridge you to that future into the mid-2030s over the course of this presentation.
The depth of our science, that we have depth in each one of our therapeutic areas, leading science, which we think can continuously generate important medicines to redefine the standard of care. When you look back, we focused the company over the last decade, and many of you were with us on that journey. It is a good health check to say, "Is that the right approach?" You can see here, once again, when you roll forward another year, 8% sales growth CAGR, 15% core OpInc CAGR, and over 1,000 basis points of margin improvement, showing that our focused strategy is delivering results from a financial perspective. When you look at our free cash flow, we said last year we want to be a cash flow generation machine. It is what allows us to invest in the business and invest in innovation.
We closed last year with $17.6 billion, $14 billion in nine months year-to-date, well on our way to getting to over $20 billion of free cash flow. That also has helped us continue to drive up our return on invested capital, demonstrating that we are efficient in how we deploy that free cash flow into the business. When you look at our total shareholder returns over this period, 275% in the 10-year view ahead of the peer median, 131% in five years, 75%. In every benchmark, we are trending ahead of the peer median. I think, again, demonstrates we are being efficient in how we generate value for our shareholders. Now, we keep our strategy unchanged. This slide has largely stayed the same over the last five years, and we believe that served us well.
Having an organization that is incredibly well-focused on our key priorities enables us to focus on execution. We remain focused on four core therapeutic areas. We will go through each one of them over the course of today. Our technology platforms, we are always evaluating, and we can have conversations today as well on how we think about each of these technology platforms as we learn more, but we believe these are the right ones for us. The four priority geographies, we are unique in the industry in having a 50/50 U.S. ex-U.S. sales split. Currently, still more international, so more 55/45. We expect it to trend to 50/50, but that allows us to be a very global company and drive growth across geographies. Then continuing to work on our foundations. We will talk about that a bit with ESG.
Lastly, continued operational excellence as manifested in that margin improvement that you see over time. We also did a look back from a 10-year view on how did we invest that capital and how consistent have we been on that capital allocation priorities. This remains unchanged, but when you take a look back, $104 billion in that period back to 2016 invested in core R&D and CapEx, $63 billion in M&A and BD&L, $140 billion returned to our shareholders through dividends and buybacks, and a 20% reduction in share count. So a balanced capital allocation. We believe this has served us well, and we plan to be consistent with this as we look ahead and into the coming period, with, of course, the knowledge that we have this cash flow generation and allows us to consistently invest in the business while also returning proceeds to our shareholders.
Now, in 2026, we weathered another LOE in the company's history. For those of you who have been with us for many, many years, we were able to navigate Diovan, Gleevec, Gilenya, and then this year, Entresto, Tasigna, and Promacta, and continue to grow. In quarter three, as we talked about last month, 4% sales growth, 10% core OpInc growth. On the full year, we expect to grow low single digit, with core OpInc to be in line to low single digit. So growing through these expiries. I think it is worth noting, especially when we will have many conversations about the early 2030s, this company has a track record of generating innovations that allow it to grow through these periods. My full expectation is we will grow through as well that 2030 period, as we will discuss in a moment. Not having a slide issue. Okay, perfect.
When we do the guidance, we guided to 5% sales growth, 2026 to 2031 this morning, 40% core margin. I would like to unpack that a little bit and then turn to the longer term before moving to the pipeline. When you look at the how do we get to the 5% to 2031, and notably in 2031 is when we do expect the Kisqali U.S. LOE, we currently guide to a mid-year effect there. We have the generic impacts through 2031, but we see very strong growth in that in-market growth drivers as well as the base business. Then when we look at a probabilized pipeline and we take a conservative view on the pipeline, this gets us to that 5% growth, and we will go through a little bit further on why each of the growth drivers we have confidence in.
When we look at this profile, we think it is something we can deliver on, and then if we are fortunate in how our pipeline delivers, can certainly do better, and we will see how that unfolds over the coming years. On the peak sales, we had three brands we upgraded, but I did want to say it for a moment, we remain confident in our $10 billion Kisqali guidance, and I am sure we will have conversations today on how we see that trajectory. For Rhapsido, we upgraded with the RMS readout to $8 billion plus and maintain multi-billion dollars across the various indications that we expect readouts on. Cosentyx, we expect actually peak to hit next year, given that in 2028 we will have the IRA effect on the brand, and we continue to look as well to see how we can maximize the overall timeline before LOE for Cosentyx.
We are upgrading KESIMPTA up to $8 billion from $6 billion. That is based on very strong performance we see across the globe. SCEMBLIX and Leqvio as well, based on the first-line performance we see in SCEMBLIX, as well as the strong dynamics we see both in the U.S., but as well as in Europe and Asia on Leqvio, gives us confidence to move Leqvio up to $5 billion and then maintain the guidance on the other brands. This is the core of why we believe on that five-year growth that we outlined. Also the commercial execution we are seeing across the globe. I think one of the things that shifted about Novartis, we had a track record of many approvals, but not always the best launches.
Now when we start to benchmark our launch performance, we are at the top end of the peer set in terms of our ability to deliver on launches. You can see here, with cases like Kisqali and SCEMBLIX, already getting the 65% in early breast cancer or 33% in the first-line CML setting. Cosentyx, you know well, but with Rhapsido already 26% CSU share in the first year. Very strong NBRx growth for Leqvio and Pluvicto. Then across the globe, number 2 in China, number 1 in Germany, number 3 in Japan, always number 1 or 2 in our international markets. That gives us that ability to take these medicines, go global, and really generate growth. Oops.
Now, when you look at our late-stage assets, we have also provided some additional guidance on the outlook for some of these late-stage medicines, with multi-billion dollar peak sales guidance for the various medicines. With CRM, abelacimab, farabursen, and pacibekitug, we will talk about those. Immunology, ianalumab, and our new disclosure today on GHZ339 in atopic dermatitis. In neuroscience, I will walk through in a little bit our outlook for del-brax and del-desiran, as well as votoplam. In oncology, late stage or approaching now filings for pelabresib and Actinium PSMA. 10 late-stage assets with multi-billion dollar potential, and we will talk in a moment about how that fits into that long-term growth guidance. Taking together our strong in-market assets and robust pipeline underpins that growth.
I do want to highlight that we are maintaining our 5%-6% growth outline for 2025-2030, providing the new guidance of 5% out to 2031, and then this mid-single digit into the mid-2030s. With the de-risked in-market brands being the foundation for that, and then the pipeline, which is, of course, continuing to expand as we advance new medicines to help solidify that growth profile. Diving in a little bit deeper, I think a lot of the discussion today I know is going to be in this post-2031 period. What we tried to outline here is a little bit of the story as we see it from the consensus. The consensus sales at $70 billion in 2030, when you fast-forward that to 2035, currently roughly $64 billion today.
You have a gap, you could say, if you take our mid-single digit guidance of around $20 billion versus where we would see ourselves and where the current consensus sees us. We think there is a way to bridge that over time. I mean, of course, we will have to continue to deliver our clinical data, but when you look at our in-market brands, our phase III and phase II high-value assets, and our internal pipeline inflows, which we have already in phase I, as well as expected inflow from research based on historical precedents, and then our normal flow of external innovation, we feel very comfortable with that mid-single digit guidance.
Going into a bit more detail on how we get there, when you think about the kind of brands that we see, or the brands where we see that we are ahead of consensus out in those outer years, Rhapsido, SCEMBLIX, Leqvio, where if we see continued momentum, could even be a larger medicine over time, especially with various outcomes data that we will have in the secondary and primary prevention setting. A large number of assets, which we will have, I am sure, many conversations over the course of today, that of course need to de-risk, but we take them from a probabilized standpoint out in those outer years. Then, real improving productivity, or I think a really dramatic improvement in our productivity out of biomedical research, which gives us a steady flow of assets.
Some of these assets now are de-risking in phase I, then will move into the mid-stage pipeline. When you take a 10-year view, certainly would have the opportunity to launch and impact that growth profile in the outer years. Taken together, when you look at that pipeline, how will that ultimately manifest in the coming years? We expect 35 submission-enabling readouts, a few more to go in 2026, a number in 2027 and 2028, then 20 more in 2029, in 2030, as well as additional numbers in 2031. We typically guide on regulatory submissions just two years out, but more I think the sentiment is when you have this many readouts, you would expect us to have the assets that can drive the midterm growth through the 2030s.
Lastly, as I mentioned on R&D productivity, we are seeing these improvements in biomedical research, 25% up in terms of the portfolio entries. We are seeing faster lead optimization, an increase in our development candidates entering GLP tox studies. This is all because of the focus that we have driven, as well as the strong alignment across commercial development and research. You will see that today as you interact with the teams in the rooms, and you have seen that over the recent years, that is what allows us to focus on the assets that matter, move them more quickly through early research into the clinic, then continue to fill out the pipeline. When you look at our end-to-end cycle times, 9.1, roughly in line with the industry averages from KMR.
Much more important is what is happening with our most recent efforts in late-stage development and our highest value assets, those projects are now increasingly less than seven years. Shrinking that time, of course, also has a compounding effect on our R&D productivity. I want to walk through now each of the TAs in turn. This will help inform your discussions. I will go in a little bit more depth in certain areas. In cardiorenal, we continue to have a portfolio looking at cardiovascular risk reduction, as well as stroke prevention. You know well with Leqvio, we expect the primary and secondary readouts, but now we have an expanding program on abelacimab, which I will talk about. We continue to believe that we can design an effective program with pasireotide despite our competitor's readout in anti-IL-6.
We have a portfolio of siRNAs that we continue to advance, and I will talk more about that. I did want to highlight as well that we are now moving into the clinic on a number of assets in arrhythmia. We have a broad arrhythmia portfolio, I think one of the broadest in the industry, as well as a number of other early phase assets. On the renal portfolio, in addition to the zigakibart readout, we have iptacopan in some rare renal conditions, but importantly, farabursen, which I will talk about in a moment. Turning to abelacimab, we believe this represents a significant opportunity. We know the target is de-risked based on competitor readouts in the oral space. Just to make sure we are all level, set 24 million high-risk AF patients, 40% of that population is undertreated with anticoagulation due to bleeding risks.
That's where we focus the development program. As an antibody, some differentiation versus the oral, so you have a dual mechanism of hitting both the inactive and active factor XI, 99% reduction of free factor XI versus less reduction that at least is as expected from the orals. Good efficacy and safety data that we've seen. Our LILAC study passed its interim analysis with a very high threshold for stopping, but without any further changes to the sample size. We feel confident now as that trial goes into its final stages. We expect a readout by mid-2027 and a submission as well in 2027. On the back of that, now we're expanding the program into secondary stroke prevention, as well as multiple additional phase IIIs in planning to cover the bases.
We do believe there's a place both for a monoclonal and an oral in these patients, and we can talk more about that. Certainly, the potential exists for differentiation from an efficacy standpoint if the deeper knockdown ultimately translates. I'm struggling with this button. There we go. With respect to the siRNA portfolio, as a case study, we want to talk a little bit about QCZ484. This is our angiotensin siRNA, which had very solid data, strong data in its phase II, phase I-B study, Q6 month dosing. We see an opportunity here, given that Entresto is a multi-billion dollar hypertension medicine in China and Japan. We have large field forces in China and Japan that are well established. Can we use this medicine to continue that portfolio into the future?
That is entering now late-stage studies as a China-Japan-focused development program with a separate program in the U.S. Goal will be to go very fast and get this to patients in that region. Alongside that, we continue to advance next-gen siRNA, so including a PCSK9 now with annual dosing, where we see very strong data and are excited about advancing that. A number of combination programs as well in our siRNA portfolio, as well as looking at additional targets in that space, all with a mind to life cycle managing Leqvio and ensuring that we can build on the history that we have in cardiovascular risk reduction. With farabursen, it's our first-in-class oligonucleotide, where we have started now the phase III study, or we'll start the phase III study before the end of the year.
12 million people with adult polycystic kidney disease, 50% progressing to kidney failure. We have demonstrated volume reductions in kidney size in a phase I-B study. A lot to learn, I think, and certainly we'll learn more as we go through the phase III program. We're very excited to potentially address a very large unmet need with a first-in-class medicine, and hopefully significantly addressing the limitations of current therapy. Turning to immunology, we have a very robust effort in immunology, of course, underpinned with Rhapsido, which I'll talk more about, but also importantly, ianalumab, which I'll also go through in a bit more detail. We remain committed to immune reset, and so on top of the YTB portfolio, we do also have here our PIT565, where we're now working through dose escalation, as well as a in vivo mRNA that we've recently in-licensed from a Chinese company.
It gives us a broad portfolio of efforts on immune reset. Then a number of other efforts ongoing on bispecifics. I will talk about GHZ, but I did want to also mention that we continue to advance our IL-1 beta, IL-18, on a number of different indications, building on the legacy that we have with IL-1 beta in rare diseases. A little bit more on GHZ. GHZ is the first time we are disclosing this program. This is a significant unmet need in AD, with 45% of patients on systemic therapy not achieving adequate control. We believe this is the first-in-class IL-13 and IL-18, which we believe are complementary cytokines in the disease. We have an extended half-life here where we are hoping to eventually get to longer dosing intervals.
In our phase II-B study, we met the primary endpoint on the 600 milligram dose of 47.4% improvement in the EASI score. I think importantly here, we saw efficacy that was consistent in patients who were dupi non-responders or dupi inadequate responders, which demonstrates the IL-18 component is additive to the IL-13 component, which is something we wanted to see to feel comfortable taking this forward. We also saw consistent responses on IGA and EASI-75. Adverse events were in line with expectations, so that phase III is expected to start in 2027, and a program we are going to move quite aggressively. We are aware there are other competitors, but again, we think with this particular mechanism and the fact that we have evidence that we have an additive effect, it could be very exciting in the future. I wanted to say a word as well on Rhapsido.
I know we have talked a lot about it in various settings, but one element of the story we have not spent much time on is on food allergy. There are about 3.5 million patients with high risk in food allergy. We had very compelling phase II results where you can see here at the 100 milligram dose, 87% of patients were complete responders. We are taking forward the 75 milligram BID into 52-week study forearm, so we want to get a broad label and then also a broad patient population. When you put that together, why this medicine is, of course, so important is beyond CSU, CINDU. We have the RMS readout that is positive. We expect the SPMS readout in 2029, so already $4 billion with RMS, $4 billion with these indications. SPMS could take MS even larger.
We are awaiting the both readouts for the HS study before the end of the year, food allergy, and then chronic pruritus of unknown origin, as well as PPR. A broad range of indications we think can power this brand over the next decade. Also in ianalumab, a lot of interest, of course, on the Sjögren's approval, which we continue to expect before the end of the year, and the team can walk you through more about that. But also a number of other indications we are advancing for ianalumab. Now, I know in SLE there is a number of medicines, and there has been many disappointments over the years in SLE, so we go in with humility. But I think still, when we look at our data here for SLE, you can see that a very strong response out through the treatment window.
When we roll patients over onto the active, you can see that on the open label extension, that the placebo group comes up to the active group. A lot of indicators here that the drug is quite active in SLE. Very impressive, I think, results. As usual, we have to see how the phase III trial ultimately plays out, but we know there is 450,000 patients with moderate to severe disease, mortality two to three times the general population. If we could get a solid hit here, we think it could be meaningful. Lastly, with our anti-IL-15 medicine, one other competitor I know advancing in celiac disease, but our focus is in vitiligo and cutaneous lichen planus. Both our phase IIs here are recruiting. These tend to be very fast studies, the overall development program here is fast.
An opportunity to hopefully advance this medicine and also look at taking it into additional indications. Now turning to neuroscience, Remy, we talked about KESIMPTA will be moving forward on the Q2 month dosing. I will say a word about del-zota and del-brax in a moment, but on del-desiran, we continue to be confident that we have a path forward to get to another study, that we can navigate some of the learnings that we have. The drug, based on everything we have seen in ongoing analyses, is active and we think can be a meaningful contribution for these patients. We are working hard to do that as fast as possible, and the team can talk you through more about that. Overall in our neuromuscular portfolio, a number of other things we are advancing to continue to cover the bases in neuromuscular disease.
A continued effort as well in neurodegeneration, very hard space, as you all well know, but one we continue to focus on. Turning to del-brax, we have covered in the past up to 87,000 patients in the U.S. and EU with this disease. This is the first time we are showing the phase II data that we recently top-lined earlier this year. Potential to be the first in class in this treatment. We saw consistent trends in this disease, consistent trends favoring across the clinical measures, favorable safety and tolerability. You can see the 50% improvement in the KHDC1L, as well as the normalization of creatine kinase. We had our meeting with FDA. FDA is open, I think, and so the door is open, but we need to generate more clinical follow-up for these patients.
The expectation is to see more improvement, and this is a very slow progressing disease. We will continue that follow-up, hopefully be able to have another conversation with the agency in the middle of next year. I think also what we decided to do based on that feedback and also learning from the del-desiran readout is to extend the follow-up for the patients on trial to 36 months with an interim readout, and also change the endpoint to give us two different endpoints on the primary endpoint, some changes. You did see the timing move out a year, but that is really to de-risk the overall program, but still give us a shot on goal with the interim readout. Certainly that is something we can discuss further in the breakouts.
On DMD and Huntington's, DMD de-risks the platform. We are on track with a priority review for accelerated approval for del-zota. Also advancing additional DMD exon skippers, exon 45, as well as our microdystrophin gene therapy, both entering the clinic as well. Our hope is to systematically expand across additional exons. We also wanted to say that in votoplam, we continue to follow the patients from the phase II trial. Our previous discussions with FDA requested that we continue to see how does the effect change over time in these stage 2 patients. You can see now, we have a 52.5% difference on the 10 milligram dose versus a matched historical control.
With that data, as well as the ongoing phase III study, which remains our base case for this, is that we'll need to complete the phase III study, we do plan an additional FDA meeting in Q1 to discuss an accelerated approval path. We know there's high interest, of course, in the Huntington's disease community for a potential oral option, so looking forward as well to have that discussion. Now turning to oncology, breast cancer, prostate cancer, RLT, I'll go through each in turn in a little bit more detail. Starting with pelabresib, and here additional, first time we're really having a more detailed discussion on pelabresib in some time. This is the phase III MANIFEST-2 96-week follow-up data. You can see the improvements in the duration of splenic responses consistent over time.
We have an additional data cut that we'll be presenting at ASH, so look out for that. I think it continues to make us believe that this can be an important medicine for patients with myelofibrosis. We continue to also see the positive trend on deaths and progressions on PELA plus RUX versus RUX alone. The medicine is submitted in the EU. We're in active discussions with the FDA on a potential accelerated approval path, so we're waiting, I think, for that final FDA minutes back on that discussion. The global MANIFEST-3 study is also underway, and we're looking to expand this medicine as well into essential thrombocythemia, as well as a phase II high-risk ET study that's also planned.
Largely not in the models, at least from what I've seen, and I think a medicine we think, given our long experience with Jakavi, we can make into an important medicine over time. Now, in prostate cancer and breast cancer, in addition to, of course, the great performance that we see in Pluvicto that's building now as we launch in HSPC, we show here our phase I trial for our Actinium PSMA, where we saw very deep responses with the medicine. Actinium having a higher overall energy in a more close space versus lutetium, which is broader, has the opportunity, I think, we think, to address patients in either the post-Pluvicto setting or in certain other settings in late-stage prostate cancer. We are expecting two phase III readouts in 2028. One in the mCRPC post-taxane setting, and one in the first-line mCRPC setting in combination with ARPI.
I think it's an exciting opportunity for us to basically cover the whole space. The idea would be that Pluvicto covers earlier phases, Actinium PSMA later phases, and then, of course, you could be using both Pluvicto and Actinium PSMA to ultimately get to deep responses. In breast cancer, a broad portfolio as well. Team will be ready to talk to you more about the whole CDK portfolio, which is now in the clinic. Three different agents now advancing in dose escalation. Our pan-mutant PI3K that we recently acquired as well, which we think could be truly differentiated versus the peer set in its ability to go across mutant variants. Then both our RLT now in dose escalation for HER2, as well as our novel ADC that we recently acquired with novel payload NMTi, also in HER2 breast cancer.
Lastly, I will mention we continue to advance our Kisqali plus oral SERD combinations to ensure that we have data that enables Kisqali to be used with the combination partner. RLT portfolio continues to advance across the various targets as well as the various diseases. 20 projects now in the preclinical space, seven assets in clinical trials. I think over the next year to 18 months, we will have a lot more data to understand which of these assets could be truly the next building block beyond PSMA or SSTR. I think that's going to be important for us to know, and then also obviously to communicate to all of you. On the deal flow, these are all the deals we have done over the last 18 months or so. A few things to note. Vast majority of our deal activity is in exploratory to preclinical.
Most of the deals we do and we plan to do remain in the sub-$2 billion space. We selectively do larger deals, but we believe that having that strategy consistently over time can generate big winners. I mean, you obviously think about drugs like the ones I have mentioned today from Anthos, from Regulus, from Tourmaline, from Synnovation Therapeutics. These are all medicines that we got in that $1 billion-$2 billion or less space, and then ultimately can take them into late-stage studies. Now, turning to AI, which I know will be a big topic of discussion. I wanted to just give you a little bit of sense how we think about AI at Novartis. We want to materially move important elements of how we generate value to the world and to our shareholders. We do that through using AI to increase the probability of success of our medicines.
Industry average is currently 8% from first in human to approval. We want to, over time, get that to 12% through better design of medicines in our early-stage research. We want to materially improve cycle times from 12 years, which is our industry average, from entry in research portfolio to approval, hopefully getting that to eight years through a range of efforts that I hope some of you, if you haven't gotten a chance, both Christian Diehl and Max Lawson, have setups to show you some of the work we are doing there. Accelerating our sales growth and then meaningfully increasing our productivity. We do that on our own, but then we also do that through a whole range of partnerships, which you can see here at the bottom of the slide. Now, how are we scaling, and are we successfully scaling?
In our minds, the key here is to focus on high-value efforts and then scale them broadly so that we can actually see material effects. In research now, we have identified multiple novel targets with the help of AI. That's a huge, I think, breakthrough in the fact that if we can find novel targets, we will address more diseases and address diseases more effectively. 95% of our small molecule projects are now AI-enabled, also a large proportion of our biologics projects. We are seeing compounds that are active, increasing their activity by up to 70% with AI-enabled drug discovery. A big effort in preclinical safety, so 130,000 preclinical safety findings now mapped, and we use that to inform preclinical safety in the company. With respect to development, we have 50% more accurate trial recruitment now, and our teams are enabled to do that in weeks.
Basically, it enables us to decide where to put a study in real time to speed up recruitment. We see 25% already faster performance in clinical study reports. 90% of now all content in Novartis development is AI-assisted. We see 90% faster statistical programming in our 2026 trials. It's been remarkable to see with the recent readouts that we have had that our statisticians can completely analyze both positive and negative results in a day or days rather than months. The depth we could understand remibrutinib, pelacarsen, del-desiran was, at least to me, astonishing. Now, when you think about manufacturing, we continue to scale across radioligand, our supply chain, our drafting. We do expect manufacturing to be where we see the biggest material P&L improvements over the next three years, a massive effort to scale AI in our manufacturing units.
With respect to commercial, 100%, 90%, depending on the geography of our reps now using AI. Small things, but big gains. If you can get 90% faster patient enrollment and insurance verification, you of course will get better uptake of your medicine. We also are using this as well to speed up content creation. Now, just in closing, in the last few minutes, I did want to take a note that we've had a huge effort over the last 10 years to really change the profile of Novartis, and I think it's been a huge success story. We almost take it for granted now. Access to Medicine, second time in a row, we were ranked number one in bringing the latest innovations to patients around the globe. AAA in the MSCI Leaders Group. Our ISS is in the leaders group as well. Leader in CDP.
We were ranked to the Fortune Change the World's number one list again for our malaria program. We were the highest-ranked pharma company in Time's Most Sustainable Companies. All that work is ongoing behind the scenes now. It's just embedded in Novartis, but I think as long-run shareholders, you can feel confident that those things are high on the management team's mind. In closing, I think before we get to the Q&A, strategy is delivering. You saw the history, 8% sales growth, improved core margin, a cash flow generation machine that continues to generate more cash over time, recognized leadership in ESG measures. The growth profile is attractive, 5% sales growth expected to 2026-2031, maintaining the 25-30 growth guidance, on track to return 40% on our core margin, and expected mid-single-digit growth long-term, underpinned by that bridge.
I encourage all of you, particularly on the sell side, to look at your bridge in 2035 and ask yourself, where are your gaps? Lastly, we have a full pipeline and strong capabilities, 35 potential submission-enabling readouts, 30 potential high-value pipeline assets. I think that just shows Novartis has a track record, I think, of being one of the best R&D engines in this industry. Again, when you look at a very long period of time, that's what gives us confidence. I've been involved in that whole machinery for 20 years. It gives me confidence. Hopefully over the course of today, you'll have continued confidence as well on that R&D performance. With that, I think we'll move to the Q&A. We'll invite everyone on stage. We're going to go over here. All right, maybe I'll go in the middle. Yeah.
With me on stage, you all know well, Mukul Mehta, our CFO, Steffen Lang, our Head of Operations, Ronny Gal, our Head of Strategy and Growth. We can start. I'll start with Michael and then move across the room. I think just wait for the microphone. Oh, sorry. Matthew, go ahead, Matthew. Matthew got the microphone first.
I don't know why I got the mic first, but I did. It's Matthew Weston from UBS. Vas and everybody, thank you very much. What I would love to do is just start with a level-setting question about the new guidance to 2031. Historically, Novartis has had a very long history of extending patent lives of some of your medicines, and that's been very valuable to the company. Can you just give us highlights as to what's anticipated, particularly because 2031 now captures Cosentyx and probably the start of Kisqali? Assumed within your numbers, is it a normal and rapid erosion of those assets, or is there some assumption within there of extending life? Just to level set before we get into the conversation about the growth drivers.
Yeah. Thanks, Matthew. We take a very, let's call it, prudent view on all of the assets that would have an expiry in that period. We assume Cosentyx on its LOE date, we assume Kisqali on our settlement date, and we assume KESIMPTA on its LOE date. I think in terms of what we're working on is we have a large number of patents to support Cosentyx. We have additional patents as well on KESIMPTA. We, of course, are now engaging, depending on the timeline, with the generic entrants on the patent dance. If we were to do better than those dates, those would be upsides versus the forecast.
Thank you.
Where did the mic go? We'll go here. Michael.
Thank you. It's Michael Leuchten from Jefferies. Vas, we've seen some high-profile failures in some categories, therapeutic areas recently. As you think about the attrition rate into the beyond 2030, does that make any difference in the way you think about the de-risking phase II into phase III? If it does, what does that mean in terms of the funnel as we think about how many assets need to come into phase I in any given period to keep the engine going?
The way we approach probability of success is we do it by an asset-by-asset basis. We've moved off of, in the models that we're using to show you these numbers, we've moved off of the industry standard. It's by asset, by the data that we have, by the TA, and that's how we model it one by one. It is likely true, I don't know, Ronnie, if you know off the top of your head, but we do have probably on average, in some areas like neuroscience, a higher risk portfolio, but that's all factored in. It's not that we haven't assumed that, and that we're assuming historical rates looking forward. Ronnie, if you want to add.
I think that basically covers it. We start from the average for the therapeutic area and the asset, and we adjust whether something is first in class and first of mechanism or something is proven by our peers to move this left or right as needed. But you are absolutely right. As we think longer term, we look at more dependency on a smaller number on asset with a low probability of success inherently. We know we need to have more there because we should expect an attrition rate that will be material. I think our models are overall a little bit more conservative than a straight line down the middle of just being a bit prudent.
Steve?
Thank you very much. Steve Scala from TD Cowen. I have an observation and then a question. The observation is that when you have given peak sales guidance for things like Cosentyx and Kisqali and actually everything, to my knowledge, and I could be wrong, you had pluses at the end for many of them in the past, and the pluses are all gone today, I think. I could be wrong. Secondly, my question is, I am surprised that you are raising Leqvio estimates given that we are heading into the readout of ORION-4. I mean, should this trial fail, there would be no compelling reason to prescribe Leqvio, I believe. The trial, I think, has a real chance of maybe not being successful. It has been running for eight or nine years, ran through COVID. You are starting a follow-on PCSK9, which is not reassuring.
Why are you confident in this trial given all it has been through? Thank you.
Yeah. Steve, I think first on the pluses, it was a policy decision just to remove pluses rather than have pluses on some and not others. We think it is easier just to not have pluses. There was not anything else behind that. I think on the readout, I think it is important to note we started V2P, which will read out next year, as a global randomized powered study with FDA's approval to risk mitigate ORION-4. ORION-4 is run by the Oxford Cooperative. They had to work through a tremendous amount of challenges here in the U.K. during COVID. We have another study, and that is the study anyway that we aligned with FDA on. We are able to pool across the studies. That is point one. Point two, we already have this in our label.
The label has been updated because the FDA's view is that the overall benefit of LDL lowering is so clear, they actually just gave the outcome benefit to all of the programs, including the oral from one of our competitors, which is what triggered this whole thing, in the absence of outcomes data. Third, we do have the V1P study still running. Why would we raise Leqvio guidance? We see a combination of factors. One, the performance in U.S. buy and bill, even in the face of oral entrance, has remained very strong, and we think that that is going to continue. Second, we see very strong performance, as we have noted, in China and Japan, and there seems to be very high interest. We are moving forward with Leqvio to go to self-administration outside of the U.S. at scale.
We are moving forward on self-administration in the EU, which will then go to China. That is initially with a prefilled syringe. We are accelerating our work to get a self-administered auto-injector as well for those regions, because we think that will ultimately lead to faster uptake as well. Taking together, we felt confident based on the trends we are seeing to take Leqvio up. Peter?
Thanks. Peter Verdult, BNP Paribas. Just a couple for the new Vas on immunology. There are other bispecifics and trispecifics in development, so is there any ambition to broaden that portfolio beyond the IL-13, IL-18 that you have highlighted today? Your competitor, Bristol, have restarted their cell therapy programs in autoimmune following the safety signals over the summer. Is there anything you can say with respects to rap-cel and the potential for data or a restart of the phase II programs?
Yeah. Thank you, Peter. Ronnie, you want to take the bispecific question?
Yeah. I know. We're now seeing very encouraging results, just like you have, from bispecific in terms of breaking the efficacy ceiling in multiple conditions. It's not every bispecific that works, but it does look like some do. We're obviously taking note of that, and what you're seeing with the IL-13, IL-18 is the first one we can disclose. There are several other in earlier development, and as they generate phase II beta, ostensibly they'll become available for you. But we're going to try to de-risk them before we make them public.
I would have noticed, the IL-18 is another one we have the opportunity to move now quickly into later stage studies. On YTB323, we continue to work through the topics with the two regulators. I think we will eventually get off clinical hold, and I think we will be able to bring this medicine to these patients simply because the therapeutic benefit is so strong and the demand from both patients and investigators is so high. I think the open question is then once we launch, how will this ultimately be restricted in its use? And that's more, I think, we have to look through. I think there's also important nuances here. Are there certain autoimmune patients which are more susceptible to the IEC-HS versus others based on the severity of their disease?
A lot, I think, we're still working through as well on that front. But we remain committed to YTB323, but then also the follow-on assets that Ronnie mentioned. Sachin?
Thank you. Sachin Jain, Bank of America. Just a big picture. Maybe you can help me with my bridge post 2030. So perhaps a bit of color on how much growth is coming from the in-market assets alone versus how important the pipe contribution is. You have listed a lot of pipeline. Is the pipeline contribution about the totality, or are there two or three assets you would call out that we particularly miss model? Thank you.
Yeah, I think first to your second part of that question. Obviously, at the early stage or where we are phase II, III, it is hard to exactly pick winners. But I think if you were to just look at reasonable probabilities on the number of phase III assets that we have with multi-billion dollar potential, that helps. I think a way to think about it, let us say simple numbers, if you have a $20 billion gap, the first $10 billion, if you just look at remibrutinib, if you look at ianalumab, if you look at pelabresib, if you look at Actinium PSMA, and then both probabilize, and you take abelacimab probabilize, we think you get that first $10 billion up.
Now, I would just say as a general note, if you are missing $10 billion in 2035 and you cannot get there with the size of our pipeline, then your probabilities are wrong, right? They are just wrong. It is just unlikely that that is going to be the case. But when you then look at the number of assets we have, you look at farabursen, you look at many of the other things we talked about across the presentation, GHZ, it just takes two or three of these to hit, and you get there. It is not like you have to find eight of these to hit at a company of our scale. So, I think that is how we think about bridging that 2035 number.
We are not promising, I saw some commentary today that every year is going to be mid-single digit, but we are saying on average, we will be able to get to mid-single digit 2031 to 2035. As always, as is the case this year, when you have an expiry like Kisqali, you will go down on growth rates, but you all know that. That is just normal in this sector. The real question is, do you have the replacement power to come back out? We believe we are showing you that we do. Graham?
Thanks. Graham Parry from Citi. Just within that five-year CAGR, I was just wondering if you could talk through your expectations for the IRA impact on Kisqali and Cosentyx. As we think about sort of the next two to three years, is the growth worse and then it sort of picks back up again? Similarly, in Europe, you are flagging you have four key markets. Germany is one of them, but obviously reimbursement is getting a lot tougher there, and under MFN, launching drugs in there is increasingly difficult. Is Germany actually less of a growth driver going forwards, and will it become a less important market?
Yeah. I think on the IRA assumption, we are obviously waiting for the final readout on December 1st for IRA, but we have a reasonable sense. As I indicated, we do expect Cosentyx, based on the current LOE date, we would expect Cosentyx to peak in 2027. Then when the IRA price hits, even though Cosentyx is not a high Medicare drug, because of the spillover into Medicaid in 340B, you would see a decline in 2028. Then obviously in 2029, we have the LOE. If we were able to extend on the LOE, there would obviously be probably a different trajectory, but that is not in our core assumption at the moment. Similarly for Kisqali, with the price, you will see a drop as well in 2028, but then we expect to get back to growth.
It is important to note that in the U.S. in 2028 and 2029, you do have the Medicaid 340B effects. Again, we expect to get back to growth and get to that $10 billion in the 2030 period. Then I think on the Germany topic, look, we are still navigating. Ianalumab is our first time through. I think in general, we see the opportunity, in general, I would say, to launch in Japan as a priority market, and then do our best to navigate Germany and then the other markets. We are going to have to see how this unfolds with the different countries. We assume in our numbers that MFN continues, and that we have to moderate our sales growth in the MFN 8 markets. That is in the assumptions that you see here. If there was any improvement in the policy, that would be great.
I think Germany is high on our minds to try to navigate whenever we can. Richard?
Thanks very much. Richard Vosser, JPMorgan. Vas, it seems like the bridge is all internal, so business development upside then on that $20 billion gap? You talked about normal pace of business development. Is that $2 billion-$3 billion a year spend, and then that contributes to the pipeline thereafter? Just thoughts there. Thanks.
Yeah, I'll let Ronnie also comment. But when you look historically, we're generally in capital deployed in M&A BD in this kind of $3 billion-$4 billion range. I mean, just look at the historical averages. I would expect us to continue on those historical averages, and that the historical contribution into our pipeline from M&A BD is also what we assume on our inflow numbers that you see here. But we think we can get most of the way there based on what we have in-house. There's no assumption of a big M&A deal or M&A is why we have conviction on 2035. We have conviction because of all the assets that you've seen here that we already have in the organization. Ronnie?
I guess one, two, three. So just the direct answer is there is some contribution from M&A and BD or partnership in the 2035 numbers. We expect long term about half of our revenue to come from external assets, and if you kind of look at the assets we already have that came in from external, they're already part of the argument. We will stay there. Clearly, there's a lot more externalization for us to pursue. Second, in terms of kind of like our areas of interest externally and how much we will spend on it, the expectation is, like as Vas said, several smaller to mid-sized deals and an ongoing kind of like feeding of assets into research early on that we then take on. And once in a while, if you look at our free cash flow, we'll have room for a larger deal.
If the right asset appears and we believe there is a significant chance for us to have a breakthrough medication through external asset, we'll certainly consider that internally. I know we'll quickly turn over.
I think not much to add, Richard, on top of it. The only other thing I would say is that we've spoken about when it comes to external BD efforts, we talk about sub-$2 billion. Sub-$2 billion deals practically will add nothing from a midterm guidance perspective, and probably would have a marginal impact, if so, beyond 2031. Clearly, I think to Vas's point, our belief on the company delivering that mid-single-digit growth longer term comes from the fact that R&D as a percentage of sales for the organization is expected to remain the same, which means as the company grows, the $10.5 billion that we've spent last year would actually become, by the end of the decade, would become a $13 billion cost block. That is going to give us what we need to deliver that top-line growth.
Florence?
Good morning. Florent Cespedes from Oddo BHF. A question for Mukul, regarding the margin. Maybe could you share with us how you see the margin reaching the 40%+ level in 2029? Is this level sustainable given the, let's say, the volatility you may see during this period and beyond, given the LOEs? Thank you.
Yeah. Thanks for the question, Florent. So, our belief remains that we will get 40% margin for the company latest by 2029. We're very happy with how the margin has progressed this year, ahead of plan, actually. That is the reason that we have actually upgraded our core operating income guidance for this particular year. There's going to be some pushes and pulls as we look forward. So the pushes, the negatives for us would be we have to deal with the Entresto generic in Europe. We have to deal with the fact that other revenue, which is basically a profit-sharing agreement that we have on ZOLGENSMA, is going to put pressure over the next two to three years of about 2% on the margin.
As previously mentioned, I think we have to deal with the IRA for Cosentyx and Kisqali in the U.S. in 2028 and beyond. Those are the pushes. The pulls for us is the growth that we are expecting on the top line, while being very, very clear that we are going to generate productivity on all lines. R&D as a percentage of sales remains the same. COGS, we have in play massive productivity efforts, but gross margin is expected to stay constant because the portfolio moves. SG&A as a percentage of sales would be a line that'll go down. So, what I'd say is we will finish this year, we will have three significant items pushing it down, and then we have our productivity efforts and our sales growth pulling it up, and we should be back to 40%.
And beyond 40%, to your question, is that a sustainable number? Absolutely, yes. All of the productivity efforts compounded with AI would help us keep it on that level.
James?
Thank you. Thank you. James Quigley, Goldman Sachs. I've got a quick question on AI, and I know we've got the session later, but from your standpoint, Vas, how well-equipped is the industry and Novartis to deliver here? We've had a lot of big promises from the AI companies about how they will influence drug development and disease progression over the years. Just interested in how you see that risk from non-pharma companies, and then also from a data perspective, how much more data is needed in order to really make AI a powerful tool?
Yeah. So, just broadly speaking, I think where we'll be able to see AI's impact in the shorter term is, the way I like to think about it is, you have information latency, operational latency, and biologic latency. Information latency is how fast can you get all the information you need to make decisions, and AI is incredibly fast at that. That information latency, so if you take that 12-year period, information latency is, let's say, a year to a year and a half of that. That you're going to get down to zero over time. Operational latency is what it takes for us to set up all these trials, write all these documents, do all of the work, design the experiments, implement the experiments with people and animals, and that, of course, is, let's say, on another two and a half years of that four-year part of that cycle.
That you can also shrink down over time, won't go to zero. The hardest part about this is the biological latency, where we actually need to see how these molecules work in a biological system. If anything, the readouts for us, for across the industry, show this is really complex, very hard to predict. The question is, how fast will AI start to be able to understand biological systems so you can reduce biological latency, so you can actually understand and predict what happens in biology? That, to me, you have to run this through eight years many times in order to do that. So that's going to take time for us to compress that. So that, I think, is the overall frame, when I look at it.
Most of the focus of the companies has been, of course, external companies, AI companies, is to design better molecules, design better ligands in the hope that they have strong pharmacological properties to then ultimately accelerate the rest of drug development. I think they are getting very good at that. We are very much working on that ecosystem. What we believe is that having all of the data for, in our case, and you can learn from Christian about this later in the day, data42, all of our data well-organized, is that we can get to the biological insights, cycle that back to the research labs, and hopefully get to both speed and probability of success faster because we have 25 years of data and can put external data sets in. Otherwise, you can't solve these biology problems. It's not an engineering problem, it's a biology problem.
I think that data is going to be hugely important, but we are going to have to keep generating more data, for sure, and keep adding more data over time. Now, what will eventually happen is this will all compound, and I think in a decade, we are going to see a very different story, and you might actually get to a much faster rate of change with AI enablement. I still think the fact that we are the companies, like Novartis, that do the experiments in that biological part of this process, and therefore generate massive insights, that's where our competitive advantage sits. It's in that data and the fact that we can generate that data. Seamus? I will come back to this side.
Thanks. So, two questions. Vas, I think you were pointing out the opportunity to continue to improve on gross margin, or sorry, operating margin across the board. What is the threshold that you think is a kind of sustainable long-term threshold, kind of sticking with 40%, but we have seen other companies go to 48% and then replenish the pipeline very effectively when you have mega brands? Then just kind of tagging on to that, you have one of the more complex overall portfolios, which I think speaks to the durability of the opportunity, but I think without the sort of mega-sized brands built in there-
Yeah
getting to that sort of, let's call it higher 40s, would seem challenging. Just interested how you think about that.
Yeah, I'll also hand it to Mukul, but I think there's a few structural differences in our business, which we think are good things, but then lead to us having maybe not the same level of margins as some of our peers. One, as I mentioned earlier, over time, we'll be a 50/50 U.S. international business. Some of those peers with very high margins have 70%, 80% range U.S. businesses. That, of course, is attractive from a margin standpoint, but you could argue, I mean, both a mission standpoint for Novartis, but also in terms of our profile, we're more diversified. Diversify the risk, diversify as well in terms of pulling the margin down. Second, you are correct. We don't have mega brands, but we have, on our count by the end of the decade, the most $5 billion plus brands in the industry.
We have a lot of $5 billion plus brands. It's better than having too many $2 billion plus brands, and you don't get the efficiencies. But because of that, we're not as scaled, let's say, on one obesity drug or one immunology drug, and that, of course, leads to some lower margins. All that said, I mean, we do believe we can be in the 40s over time, but what we won't ever want to do is compromise on the R&D investments. I think in the end, and we have, of course, other peers that go even lower on the margin and higher on the R&D investment, we want to maintain that 20% plus R&D investment, and that has to be the core of the P&L in the long run.
Yeah. The only two things I'd add to what Vas said is, one, we have to recognize what the company has done from a profit margin improvement perspective. We showed this slide before, 1,000 basis points improvement over the last 10 years. We believe that getting to that 40% by 2029 and maintaining it from there gives us, as a company, a lot of flexibility to invest on what the company would need when the company becomes a much bigger company going into mid of next decade, which is R&D. The two lines, which is the two other lines, which is COGS as a percentage of sales, we're best in class. Now, no two companies are comparable because we have to look at what's the complexity of our portfolio, which you mentioned as well.
But we feel we are, from COGS as a percentage of sales, we are best in class. Then from SG&A as a percentage of sales, we were not best in class a few years ago, but now we are in that top tier, and the idea would be to remain in that top tier going into the next decade.
Ben?
Maybe this is a follow-up to that. Hi, it is Ben here at RBC Global Asset Management. A follow-up to the AI question. You are saying your project timelines are now about seven years. Plausibly, does that fall to six years in the next few years as AI and all this operational latency falls? Then if you think about the overall industries, say phase I success rates are still, at the moment, 10% getting all the way through to the end. If our science gets better than this in AI, does that plausibly go to, say, a 15% success rate and then put that over your early stage and you are a year or two faster at a slightly higher rate, and that powers us in mid-next decade? Or how should we think about that? Thanks.
Yeah, I think on speed, I think the averages, it is important to look at it, where we talk about averages or certain therapeutic areas. Certain therapeutic areas, of course, cardiovascular, et cetera. But I do think that we are seeing that we can be on average in the seven year, and could we get that in the clinic down to six years? Then if you are down to three years over time in research, that is nine years versus 12 is the industry benchmark today. So, we think about our roadmap we are trying to get to is, on average, can we get from 12 years down to eight, from when we first have a portfolio entry in research? Industry standard now is three to four years in research, and then eight to nine years in the development. Can you get that down to be much faster?
I think that is doable and that is tractable in the five to 10 year period. Then you should see us as an industry, and we think Novartis, because we are scaling this faster than our peers, in our view, some of our peers at least, we will see those benefits sooner. I think on probability of success, this is a longer journey. I mean, I think that the reality, as I noted, 8%, some statistics has it falling down to 6% on the industry average from entering into humans and ultimately getting to the finish line. That is all going to come down to how fast we get better at solving biology. As you know, our industry, I have a view that this will take longer.
There are folks in the tech sector who think that solving that biology and be able to model what happens in a cell and then what happens in 40 trillion cells in this very complex dynamic is going to be something that you can solve much faster, and then you will see probability of success go up because you will be able to model the impact of hitting this target in this complex system, and then make even more streamlined decisions on the line, and then you see POS go up. It is a debate. I think we, of course, have been doing this a long time, so we are maybe colored for good and bad by that reality, but that is why I would say that is a 10-year-plus journey to really get POS to move. Please. Oh, actually, maybe here in the front. I do not know your name.
Thanks. James Gordon from Barclays. One question was REMI-HS. I think you said on the Q3 call that you hoped to have the data by today, and it hasn't yet reported. REMI-HS didn't seem a big focus in the presentation today, so I could see food allergy getting more of a slide. Is that partly reflecting a more bullish view on food allergy versus HS in terms of chances of success or the commercial impact that that would have, or just a chance? Also just a clarification on the margins, and I noted the AI discussion panel later today. The margin guide you've given, does that already include a big benefit from AI? Actually, if AI goes as well as you hope it will, could that actually be some significant upside?
Have you baked in big efficiencies already, or they're really further out?
Yeah. First on REMI-HS, we're still waiting for the results to come in across both studies. The timelines didn't work out such that we could get them by meet the management. The reason we highlight food allergy is when we look at big indications, we think this is a large indication opportunity. We see HS, when we look at our Cosentyx experience and we look at the dynamics in HS, we see HS as a billion-plus opportunity on the brand, but we see food allergy as a massive opportunity, hence highlighting that. Nonetheless, we think with all of these opportunities, CPUO and rosacea, et cetera, we'll be able to, over time, get to a very large medicine. I think on the margin, Mukul?
Yeah. The productivity gains that we would make out of AI in this timeframe between now and 2029 are baked into the guidance that we have. I mean, we have to assume that AI will have, I mean, most of the impact that AI will have, and we will talk about, is around R&D productivity. Hopefully, it leads us to more value being generated, but it will have some productivity impact, including a reduction in what we believe is the external cost that we have as a company, which is $11 billion. Part of it is already in the P&L, and we have baked in some more productivity going into the next two years.
Yeah. I think if we were to accelerate our AI transformation, that, of course, could be an upside versus the margin profile that we currently have. Simon?
Thank you. Simon Baker from Rothschild. A cardiologist in Nature recently said that you could not have hoped for a better evidence base for Lp(a), and it did not work out, which is why it is such a big surprise. I just wondered generally what lessons you take for that going forward, and specifically onto IL-6, where the evidence base was equally compelling until we had this ZEUS disappointment, yet you seem very confident that you have a good molecule there. It would be good to get your thoughts on that. Thank you.
Yeah. I would say we are never very confident in cardiovascular outcomes trials, but nonetheless, we, I think, thoughtfully try to pursue them. I think on Lp(a), many of you saw the presentation of AHA, quite, I think, a clear result. I think it remains to be seen on primary prevention. I think one of the learnings there is that when you control a risk factor with LDL to the level we were able to control that risk factor in the study, that is not the natural experiment that we are basing a lot of our understanding on. I think when LDL is moving and then you have elevated Lp(a), that is kind of what we have based a lot of our understanding on these natural history cohorts. Here, we have taken it down to below the very now rigorous guidelines, and then it is hard to show an impact. We will see.
I think on Lp(a), we are still trying to decide the right path forward, if there is a strong path forward for our once-yearly asset. On IL-6, we come at that because of the CANTOS experience as well as our understanding. We have done other studies in this post-acute setting. We believe the biology here supports it. I think in the end, in our industry, we have to follow the biology. Sometimes it works, sometimes it does not work. But if we are afraid of following the biology when the biology is clear, then we can shut down the whole operation here, right? I mean, in the end, if the biology is clear, we have to follow it. Sometimes medicine goes our way, sometimes it does not.
Just to add to that point, there is an hypothesis that post-myocardial infarction, inflammation is causal in further sequela, right? We do not know for a fact that that is the case. We will run the trial, but we believe there is enough evidence out there to deserve a proper test. Is it a higher-risk trial than other trial? We can probably fairly say yes. But we believe it is kind of like our role as a company to test that hypothesis.
Yeah, and we think we can do different things from a design and endpoint standpoint that differentiates versus the current study that we will soon read out. Please.
Yeah, thanks a lot. Urban Fritsche from ZKB. Follow-up on the long-term margin. As you have explained that IRA is already having an impact through 2029, how big of a dip should we expect once Kisqali and KESIMPTA is going, and how we should think on the margin through that time?
Yeah. I think we have not given guidance on margin beyond 2029. But what we can very confidently say is that we as a company would stay on that 40% plus guidance- margin levels beyond that particular point. What we have to think of, what is the company doing? What is the company going to become by then? If we take the company from where it is today and say 5%-6% between 2025-2030, or we say 5% 2026-2031, we as a company would be a $70 billion plus company with a core margin of 40%, gives us enough to continue to invest into the future of the company. Vas clearly said, I think right now what we know on AI, from what AI can do from a productivity perspective, is modeling.
Now, if we accelerate, if the world accelerates, if this ends up in more productivity, then that would actually be a catalyst for more upward push on that margin, basically. But as it stands right now, I think with telling the market that we will stay on 40% plus beyond 2029 gives us enough flexibility to continue to invest in R&D, which is what the company would want to do.
Matthew.
Can I ask a question about manufacturing and infrastructure? Novartis was one of the largest numbers that was given at the time of MFN for investing significantly in the U.S., and I think a lot of that was you were also one of the companies where your manufacturing infrastructure was least exposed to the U.S., despite it being a target of 50% of your revenue. There has been a lot of debate in the industry, particularly as MFN has a fixed timeline currently, but also after some of the recent political outcomes in the U.S., as to the industry's commitment to that re-onshoring in the U.S., or whether we will see investment moving back to Europe. I would just love, as a real leader in the industry, and particularly a leader in that U.S. investment cycle, what is your thought as to what we should expect over the next few years?
Stefan, yeah.
Yes, thanks for the question. Yes, as we communicated, we are building out our manufacturing footprint in the U.S. to be able to locally supply, as of 2029, all branded and key products for us locally. This journey is underway, the investments are up and running, and we have the factories being built out. This is building on the existing presence we already had, which we also further build out radioligand therapies. I think we have a strong footprint already, and we have announced, and we are in the process of adding facilities in Florida and Texas. For sure, given the importance of the market and the valuation of innovation at the market, we continue to follow this plan.
Yeah, and I think to add on what Steffen's comments, when we think about it, when we took the decision to add these nine facilities, we were made aware, let's call it, by the political establishment in the U.S. that the U.S. soon will, at least in the Novartis case, be half our sales, and we don't produce really anything meaningful in the country. I think it's a prudent decision for a company in the long run to be producing its medicines in a country where it's half of the business. Now all of our key medicines will be produced in the U.S. for the U.S., which just insulates us from whichever way politics goes in the future. It's similar to, in many ways, what we do in China. We produce in China for China, Europe for Europe.
It's very odd that the largest market and most profitable market, we don't have that footprint. The next question is, what about the cost of goods? There is a cost of goods shift in producing more in the U.S., but the volumes are relatively small, so we can absorb the cost of goods difference. Of course, Steffen is, I think, the best in the industry and his team at using robotics, automation, technology to drive down our core cost of goods, as Nicole mentioned, to our assessment, the lowest in the sector, despite having RLT in CAR-T. I think it was a prudent decision overall. Please.
Thibault Boutherin, Morgan Stanley. You just touched on China, and obviously we see a lot of innovation emerging from China right now. It's very fast-paced. For any new mechanism that is emerging, we see a lot of follow-up molecules with improved design. Just wanted to have your thoughts on this, in particular in terms of speed of replacement of portfolio, having follow-up molecules and so on. Then just a quick one on farabursen. Regulus used to mention the potential to file for accelerated approval based on the phase II data. Just wanted to know if it's still something that's under consideration.
Ronny, on China?
Yeah, we are seeing a growing pace of innovation in China. They have now reached the point where the molecules they produce move away from being simply follow-on molecules to some molecules that are either first in class or essentially a substantial enough improvement over the existing early class that they hit our screen now. Novartis has done more than 10 deals in the last 18 months in China, and we will continue to bring assets in from China when they meet our criteria of being sufficiently differentiated for us to launch them globally and benefit patients everywhere.
The pace of innovation in China does put pressure on the global industry to move faster, but we are part of that movement to move faster in the industry, as you've heard from us, and it's better for the patients, for the long term, all this just benefits patients more.
Yeah, I think on farabursen, our expectation is we need to do the phase III study. When we close out fully the phase I-B, we'll certainly evaluate. But I think when you look at the timelines, we think it is also going to be valuable to have a robust efficacy and safety data set to ultimately file with. Sorry, Michael. Cycle back through.
Thank you. It's Michael Leuchten from Jefferies. Can I ask a question on supply chain and radioligand? If your actinium agent hits in the head-to-head, what does that do in terms of actinium supply versus lutetium, and what does it also do from a margin perspective?
Very important. Steffen?
From a supply chain perspective, we are looking forward to the launch, and we have a robust supply chain set up in place for both the isotope and the product manufacturing. This will also benefit and will be complementary to the engine we have set up for Lutathera and Pluvicto with regard to planning, then execution, and the entire logistics, which is showing that we can deliver Pluvicto year to date at 99.8% customer service level. From a supply chain perspective, we are ready, and we are looking forward to the launch.
I would add that actinium does have a higher cost of goods than lutetium because of the production of the isotope. But with Actinium PSMA, we no longer have the royalty burden that we have on Pluvicto. I think it is a challenging manufacture, but Steffen's team is fully able to manage that. From a profitability standpoint, actually advantageous Actinium PSMA versus lutetium PSMA. Sachin? I think this has to be looking to five minutes more? Okay.
Sachin Jain, Bank of America. Two pipe questions, please. If you could update on ianalumab Sjögren's and how the regulatory conversations are going, and is the subgroup anything related to what Amgen presented on the systemic subgroups? Just any color there. Then on abelacimab, you obviously passed an interim, the studies versus placebo. Perhaps you could just give us some sense of what the study's pattern, what we viewed as clinically meaningful at the end.
Yeah.
Our feedback is in the 50%-60% range, and that would imply an interim much above that. Just any color there would be helpful. Thank you.
Yeah. First on ianalumab, we're hopefully in the final stages of the discussion with FDA. I think the question from an FDA standpoint is how to best characterize the patients who most benefit from the therapy. I think exploration of could there be certain, and I don't want to get ahead of the FDA, patient characterization either in section 14 or in the label indication on the patients that benefit most. I would note, I hope you all took a look at our two-year data that we presented. I mean, what you saw there, I think, was quite impressive, the fact that patients' responses to ianalumab are deepening over time. You have more and more symptom benefit over time as well, and some of those numbers are quite meaningful.
Our discussion with experts at the congress was actually quite positive, and I think that we're seeing a lot of pent-up interest in ianalumab because as they see that, unlike in other areas like HS, where the two IL-17s lose efficacy at year one, with ianalumab, we seem to be seeing deepening efficacy over time, which I think will bode well for the medicine. For abelacimab, we will have a design paper published soon. I'm not exactly sure when. What I can say is we allocated very little alpha to this interim analysis, so it would have had to be efficacy that would be better than agents like warfarin to ultimately stop this study. I wouldn't read into anything at the study not stopping.
But I do think the fact that we don't need to make any other study changes at this point, given the feedback from the DMC, is why we have now confidence to do the additional trials that we're outlining right now. Florent? I think somebody has to give Florent the mic.
Mic.
I'll give it to you, Holger, next.
Thank you very much. Florent Cespedes from ODDO BHF. A follow-up question on abelacimab. Could you maybe share with us what is behind the multi-billion dollar opportunity, and why did you not start the other phase III clinical trials earlier? Are you waiting for the first clinical trial readout? Any color on that would be great. Thank you.
Yeah. I think we always thought that it had multi-billion dollar potential. Now I think the size of the opportunity will depend on its relative profile to the oral, and if the oral readout in AFib is ultimately positive. If the oral readout in AFib is not positive, then obviously our potential goes quite a bit higher, I would say, very large. Otherwise, if we're splitting the market with orals. Then I think with respect to the decision on secondary stroke prevention and adding the additional indications was in part seeing the oral from the other competitor that ultimately worked in secondary stroke prevention, which gave us more confidence that the factor XI mechanism was de-risked. Then now our greater enthusiasm is now passing this interim, and knowing that feedback, I think we have more conviction to move forward. I think, Holger, you've been waiting. Holger?
Holger Blum from BZ Bank. My question is on the technology platforms, where I think in the past you emphasized the importance very much. Today, it felt a little bit shorter. Why do radioligand therapies, or maybe a year ago you mentioned some need in bispecifics in oncology where you could add some more strengths. How important are these technologies of filling the gaps, not just on a therapeutic focus, but really on a portfolio approach.
Yeah, I think no change in deliberate change in emphasis on technology platforms, maybe just slide and timing limitations. I think on RLT, continue to believe this can be a significant platform, $30 billion market opportunity. You saw with siRNAs, not only in cardiovascular, but we continue to advance the conjugated siRNA platforms in neuromuscular rare diseases. We, of course, talk about the transferrin receptor conjugates, but we also have a lipid-conjugated technology we take into Charcot-Marie-Tooth, amongst other diseases. So the siRNA platform. CAR and cell and gene therapy, of course, we're right now navigating a range of topics, right, to figure out where is the right place to go. Our view remains that in very severe diseases, like late-stage immunology diseases, like late-stage neuromuscular or severe neuromuscular diseases, benefit-risk is clearly positive.
But as you know, more we're learning, especially with CAR, more recently on the safety topics. Ronnie, anything you want to add on platforms?
Yeah, so two things. First of all, you will see we're moving our second-generation gene therapy into the clinic in rare conditions. We think that will be a significant innovation. Second, the discussion that Vas mentioned, the deal we did with Abogen, that is an in vivo mAb approach, which is a new approach we're adding. I probably say that kind of from my impression, what we are doing with some of the others is reaching nice maturity. So the RLT movement, the RLT approach is moving from two assets that we brought in through acquisition to a situation we are moving in multiple assets that are internally developed forward. On siRNA, again, same thing, moving from Leqvio, externally developed, perfected internally, manufacturing system, now moving into multiple areas.
I think the focus today has been mostly on telling you about the growth to 2035, so naturally focusing on assets, but the platforms are moving ahead and with kind of full speed.
We really appreciate everyone again being here. I hope you have a great day. We will now move to the breakout sessions where you get to talk to the teams, who can go into much greater depth on many of the topics that we covered, and look forward to having a great conversation. Thank you again.
Thank you.
Thank you. Thank you. Everybody got a question. It is good.